22 Oct 2018 07:00
C4X Discovery Holdings plc
("C4XD" or the "Company")
PDMR Shareholdings
22 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that Dr Craig Fox, Chief Scientific Officer, has today purchased 5,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), at a price of 86.7 pence per Ordinary Share (the "Dealing"). Following the Dealing, Dr Craig Fox holds 7,183 Ordinary Shares.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Dr Craig Fox | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Chief Scientific Officer, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 1p ordinary shares
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 19 October 2018 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications 020 3709 5700
Mary-Jane Elliott, Matthew Neal, Chris Gardner
About C4X Discovery
C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards pre-clinical licensing discussions. In selecting and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.
The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com
--ENDS----